A new study coauthored by investigators at the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, showed the effectiveness of a scoring system enabled by a LIMR-developed assay in predicting drug-induced torsade de pointes (TdP).
TdP is a life-threatening form of ventricular tachycardia that often occurs as a result of the heart taking longer to recharge between beats, or QT prolongation. Clinicians have known that certain approved and experimental medications can inadvertently cause QT prolongation. The risk is so great, in fact, that the U.S. Food and Drug Administration (FDA) now requires all drug candidates in development to be tested to ensure they don’t cause QT prolongation before entering into clinical use. But testing in patients isn’t always possible, so the FDA has called for preclinical testing methods.
LIMR professor Gan-Xin Yan, MD, PhD — along with colleagues at the FDA, Janssen Pharmaceuticals, GlaxoSmithKline and Peking University — demonstrated in a recently published, blinded study that the Normalized TdP Score System they developed successfully predicted the proarrhythmic risk of 34 medications.
To complete their study, the team used Dr. Yan’s arterially perfused ventricular wedge preparation (‘wedge prep’ for short), an invention previously shown to accurately record all electrical signals in the heart, even in its innermost layers. Previously, scientists could record only the signals sensed on the outside of the heart.
In the current study, researchers used Dr. Yan’s wedge prep to detect signals on the inside of animal hearts, each of which had been treated with one of the 34 studied medications. They then assigned scores to those drugs, thus enabling an accurate risk assessment of a medication’s ability to induce TdP.
“There has long been a need to reliably predict TdP risk among drug candidates,” said Dr. Yan. “We’ve now shown that using our normalized TdP score by the wedge prep assay can enable pharmaceutical researchers to readily determine drug-induced TdP risk among their compounds. We think this assay will turn out to be a best-practice preclinical drug-safety solution for pharmaceutical development and may eventually reduce the need for human QT studies.”